AU2018345400B2 - Methods for selectively expanding cells expressing a TCR with a murine constant region - Google Patents

Methods for selectively expanding cells expressing a TCR with a murine constant region Download PDF

Info

Publication number
AU2018345400B2
AU2018345400B2 AU2018345400A AU2018345400A AU2018345400B2 AU 2018345400 B2 AU2018345400 B2 AU 2018345400B2 AU 2018345400 A AU2018345400 A AU 2018345400A AU 2018345400 A AU2018345400 A AU 2018345400A AU 2018345400 B2 AU2018345400 B2 AU 2018345400B2
Authority
AU
Australia
Prior art keywords
cells
mtcr
tcr
ser
val
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2018345400A
Other languages
English (en)
Other versions
AU2018345400A1 (en
Inventor
Drew C. Deniger
Steven A. FELDMAN
Steven A. Rosenberg
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
US Department of Health and Human Services
Original Assignee
Government of the United States of America
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Government of the United States of America filed Critical Government of the United States of America
Publication of AU2018345400A1 publication Critical patent/AU2018345400A1/en
Application granted granted Critical
Publication of AU2018345400B2 publication Critical patent/AU2018345400B2/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4202—Receptors, cell surface antigens or cell surface determinants
    • A61K40/4203—Receptors for growth factors
    • A61K40/4205—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ ErbB4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4271—Melanoma antigens
    • A61K40/4272—Melan-A/MART
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2121/00—Preparations for use in therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/27—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by targeting or presenting multiple antigens
    • A61K2239/28—Expressing multiple CARs, TCRs or antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2301—Interleukin-1 (IL-1)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2312—Interleukin-12 (IL-12)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/50—Cell markers; Cell surface determinants
    • C12N2501/515—CD3, T-cell receptor complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • General Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Toxicology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2018345400A 2017-10-05 2018-09-24 Methods for selectively expanding cells expressing a TCR with a murine constant region Active AU2018345400B2 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762568339P 2017-10-05 2017-10-05
US62/568,339 2017-10-05
PCT/US2018/052432 WO2019070435A1 (en) 2017-10-05 2018-09-24 METHODS FOR SELECTIVE EXPANSION OF CELLS EXPRESSING A TCR WITH A CONSTANT MURINE REGION

Publications (2)

Publication Number Publication Date
AU2018345400A1 AU2018345400A1 (en) 2020-05-07
AU2018345400B2 true AU2018345400B2 (en) 2024-06-20

Family

ID=63841049

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2018345400A Active AU2018345400B2 (en) 2017-10-05 2018-09-24 Methods for selectively expanding cells expressing a TCR with a murine constant region

Country Status (13)

Country Link
US (1) US12227554B2 (cg-RX-API-DMAC7.html)
EP (2) EP3692140B1 (cg-RX-API-DMAC7.html)
JP (2) JP2020535832A (cg-RX-API-DMAC7.html)
KR (1) KR102757789B1 (cg-RX-API-DMAC7.html)
CN (1) CN111417720B (cg-RX-API-DMAC7.html)
AU (1) AU2018345400B2 (cg-RX-API-DMAC7.html)
CA (1) CA3077595A1 (cg-RX-API-DMAC7.html)
ES (1) ES2960313T3 (cg-RX-API-DMAC7.html)
FI (1) FI3692140T3 (cg-RX-API-DMAC7.html)
IL (1) IL273698B2 (cg-RX-API-DMAC7.html)
MA (1) MA50748A (cg-RX-API-DMAC7.html)
SG (1) SG11202003112QA (cg-RX-API-DMAC7.html)
WO (1) WO2019070435A1 (cg-RX-API-DMAC7.html)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20230124983A (ko) * 2020-12-22 2023-08-28 네오진 테라퓨틱스 비.브이. 유전적으로 조작된 세포를 추적하기 위한 펩타이드마커
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
US20250145950A1 (en) * 2022-02-01 2025-05-08 Alaunos Therapeutics, Inc. Methods for Activation and Expansion of T Cells

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2103887C (en) 1991-12-13 2005-08-30 Gary M. Studnicka Methods and materials for preparation of modified antibody variable domains and therapeutic uses thereof
AU6969096A (en) * 1995-09-05 1997-03-27 General Hospital Corporation, The Monoclonal lymphocytes and methods of use
DE19905048A1 (de) 1999-02-08 2000-08-10 Gsf Forschungszentrum Umwelt Verwendung depletorisch oder mitogen wirkender Antikörper in der Immuntherapie
JP2003274960A (ja) * 2000-02-03 2003-09-30 Japan Science & Technology Corp 可溶性ｔ細胞受容体タンパク質およびその作成方法
JP2003276960A (ja) * 2002-03-26 2003-10-02 Mitsubishi Electric Corp エレベーター制御システム
DK1545204T3 (en) 2002-09-06 2016-11-14 The Government Of The Us Secretary Dept Of Health And Human Services Immunotherapy with in vitro selected antigen-specific lymphocytes following non-myeloablative lymphodepletive chemotherapy
AU2004289316B2 (en) * 2003-11-10 2011-03-31 Altor Bioscience Corporation Soluble TCR molecules and methods of use
AU2007248019B2 (en) * 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
US8216565B2 (en) 2007-01-12 2012-07-10 The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services GP100-specific T cell receptors and related materials and methods of use
US8785601B2 (en) 2009-01-28 2014-07-22 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors and related materials and methods of use
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
ES2876176T3 (es) 2010-09-21 2021-11-12 The Us Secretary Department Of Health And Human Services Office Of Technology Transfer National Inst Receptores de células T anti-SSX-2 y materiales relacionados y métodos de uso
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
EP3828197B1 (en) 2012-05-22 2024-10-02 The United States of America, as represented by the Secretary, Department of Health and Human Services Pharmaceutical composition comprising host cells encoding anti-ny-eso-1 t cell receptors
PT2895509T (pt) * 2012-09-14 2020-03-13 Us Health Recetores de células t que reconhecem mage-3 restrito a mhc de classe ii
ES2745472T3 (es) * 2013-07-15 2020-03-02 The U S A As Represented By The Secretary Department Of Health And Human Services Office Of Tech Tra Receptores de células T anti-virus del papiloma humano 16 E6
US10174098B2 (en) * 2014-05-29 2019-01-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-human papillomavirus 16 E7 T cell receptors
EP3848456A1 (en) * 2014-10-02 2021-07-14 The United States of America, as represented by The Secretary, Department of Health and Human Services Methods of isolating t cells having antigenic specificity for a cancer-specific mutation
KR20170100517A (ko) * 2014-11-20 2017-09-04 유엠씨 우트레크트 홀딩 비.브이. 외래 면역 수용체를 갖는 조작된 T 세포의 농축(enriched)을 위한 항체 및 조작된 T 세포의 디플리션에 사용하기 위한 항체의 용도
US11207394B2 (en) 2014-11-26 2021-12-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anti-mutated KRAS T cell receptors
EP3350213B1 (en) 2015-09-15 2021-03-31 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing hla-cw8 restricted mutated kras
ES2906795T3 (es) 2016-04-26 2022-04-20 Us Health Receptores de células T anti-KK-LC-1
HUE060121T2 (hu) 2016-08-02 2023-01-28 The U S A As Represented By The Secretary Anti-KRAS-G12D T-sejt receptorok

Also Published As

Publication number Publication date
JP2024050551A (ja) 2024-04-10
EP4269595A3 (en) 2023-12-06
WO2019070435A8 (en) 2020-01-30
CN111417720A (zh) 2020-07-14
EP3692140A1 (en) 2020-08-12
EP4269595A2 (en) 2023-11-01
AU2018345400A1 (en) 2020-05-07
WO2019070435A1 (en) 2019-04-11
KR102757789B1 (ko) 2025-01-20
ES2960313T3 (es) 2024-03-04
JP2020535832A (ja) 2020-12-10
US20200254018A1 (en) 2020-08-13
US12227554B2 (en) 2025-02-18
EP3692140B1 (en) 2023-07-19
CN111417720B (zh) 2025-02-07
JP7747724B2 (ja) 2025-10-01
IL273698A (en) 2020-05-31
KR20200064107A (ko) 2020-06-05
MA50748A (fr) 2020-08-12
CA3077595A1 (en) 2019-04-11
IL273698B2 (en) 2025-07-01
IL273698B1 (en) 2025-03-01
SG11202003112QA (en) 2020-05-28
FI3692140T3 (fi) 2023-10-11

Similar Documents

Publication Publication Date Title
TWI823829B (zh) 靶向血液惡性腫瘤之嵌合抗原受體（ｃａｒ），其組合物及使用方法
CN110582509A (zh) 使用具有多特异性的嵌合t细胞受体蛋白治疗癌症
JP2021536266A (ja) 固形癌のためのキメラ抗原受容体及びキメラ抗原受容体が発現されたｔ細胞
JP7747724B2 (ja) マウス定常領域を伴うｔｃｒを発現する細胞を選択的に増幅するための方法
JP2019525771A (ja) プログラム死１リガンド１（ｐｄ−ｌ１）結合タンパク質及びその使用方法
CN107849112A (zh) 嵌合抗原受体(car)、组合物及其使用方法
WO2022222910A1 (zh) 靶向gprc5d的抗体及其用途
WO2022247795A1 (zh) 靶向Claudin18.2的纳米抗体及其用途
US20250009801A1 (en) Combination of molecular switch regulation type chimeric antigen receptor cell and antibody, and use thereof
JP2021534784A (ja) Ｂ７ｈ３キメラ抗原受容体を含む方法および組成物
EP4194472A1 (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
CA3225252A1 (en) Engineered t cell receptors fused to binding domains from antibodies
US12371492B2 (en) Humanized antibody specific for CD22 and chimeric antigen receptor using the same
JP2025540949A (ja) 疾患を治療するための人工免疫細胞、その組成物および方法
CN120035658A (zh) Nkg2d工程化细胞及其组合物
CN118420759A (zh) 靶向cll1的单域抗体及其用途
HK40031098A (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
HK40031098B (en) Methods for selectively expanding cells expressing a tcr with a murine constant region
US20250235479A1 (en) Natural killer cells expressing dual-targeting chimeric antigen receptors for cd19 and cd22, production method and uses thereof
Halim Targeting of B-cell Malignancy Using Novel Parallel Chimeric Antigen Receptor (pCAR) Engineered T-cells
HK40086008A (en) Chimeric antigen receptor comprising novel co-stimulatory domain and use thereof
WO2022121880A1 (zh) 靶向cd19的人源化抗体及其用途

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)